Objetivo The aim of this project is to perfect a living human skin equivalent using advanced culture procedures and to validate it as reliable predictive in vitro system for human skin pharmaco-toxicology. Human skin was the first organ to be reconstructed in vitro and is likely to provide a predictive system for evaluating drug efficacy and toxicity, avoiding animal experimentation. organogenesis in vitro for pharmacological studies is a very new and promising field of investigation. Culturing cells in close contact with their physiological matrix molecules and with cell types usually adjacent in vivo, cells have been shown to communicate and differentiated in this skin equivalent. These cell-matrix-cell interactions greatly modify the response to pharmaco-toxicological agents, resembling the situation in vivo and demonstrating that some pharmaceutical agents operate on the cell-cell and cell-matrix communication system. To achieve our goal, the collaboration begun during a previous BAP programme will be reinforced in order to study the role of cell-matrix and cell-cell interactions in differentiation processes and in pharmacological responses. The validation of these models with a possible transfer to industry to screen the activity of drugs on a large scale is expected for wound healing promoters, antipsoriatic drugs, pigmentogenic, antineoplastic and anti-ageing substances in the next four years. In addition, this concept of organogenesis in vitro, allowing pharmaco-toxicology at the cellular communication level, will identify pathways that might represent targets for drugs of high socioeconomic value. This first human organ reconstructed in vitro can be considered as a prototype. Most of the technical innovations made with the skin model could be applied to the reconstruction of other organs such as blood vessels, ligaments, endocrine glands, etc. Ámbito científico medical and health sciencesbasic medicinetoxicologymedical and health sciencesbasic medicinepharmacology and pharmacy Programa(s) FP2-BRIDGE - Specific research and technological development programme (EEC) in the field of biotechnology (BRIDGE), 1990-1994 Tema(s) Data not available Convocatoria de propuestas Data not available Régimen de financiación CSC - Cost-sharing contracts Coordinador Institut National de la Santé et de la Recherche Médicale Aportación de la UE Sin datos Dirección Avenue Claude Vellefaux 75475 Paris Francia Ver en el mapa Coste total Sin datos Participantes (4) Ordenar alfabéticamente Ordenar por aportación de la UE Ampliar todo Contraer todo L'Oréal SA Francia Aportación de la UE Sin datos Dirección 1 rue Eugène Schueller 93600 Aulnay-sous-Bois Ver en el mapa Coste total Sin datos Stiftung Deutsches Krebsforschungszentrum Alemania Aportación de la UE Sin datos Dirección Im Neuenheimer Feld 280 69120 Heidelberg Ver en el mapa Coste total Sin datos UNIVERSITAET KOELN Alemania Aportación de la UE Sin datos Dirección Joseph-Stelzmann-Srasse 52 50931 KOELN Ver en el mapa Coste total Sin datos Université de Liège Bélgica Aportación de la UE Sin datos Dirección 4000 Liège Ver en el mapa Coste total Sin datos